"Multiple Myeloma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
- Multiple Myeloma
- Multiple Myelomas
- Myelomas, Multiple
- Myeloma, Multiple
- Myeloma, Plasma-Cell
- Myeloma, Plasma Cell
- Myelomas, Plasma-Cell
- Plasma-Cell Myeloma
- Plasma-Cell Myelomas
- Plasma Cell Myeloma
- Cell Myeloma, Plasma
- Cell Myelomas, Plasma
- Myelomas, Plasma Cell
- Plasma Cell Myelomas
- Kahler Disease
- Disease, Kahler
- Myeloma Multiple
Below are MeSH descriptors whose meaning is more general than "Multiple Myeloma".
Below are MeSH descriptors whose meaning is more specific than "Multiple Myeloma".
This graph shows the total number of publications written about "Multiple Myeloma" by people in this website by year, and whether "Multiple Myeloma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Myeloma" by people in Profiles.
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023 03 14; 7(5):768-777.
Geospatial analysis of population-based incidence of multiple myeloma in the United States. Cancer Epidemiol. 2023 Apr; 83:102343.
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 02; 24(2):139-150.
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 Mar; 29(3):174.e1-174.e10.
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.
Evaluating the Addition of Clinical and Staging Data to Improve the Pricing Methodology of the Oncology Care Model. JCO Oncol Pract. 2022 11; 18(11):e1899-e1907.
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study. Clin Lymphoma Myeloma Leuk. 2023 01; 23(1):68-77.
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Lancet Haematol. 2022 Dec; 9(12):e897-e905.
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
Gastrointestinal, hepatic, and pancreatobiliary involvement by plasma cell neoplasms: clinicopathologic correlations in a retrospective cohort of 116 cases. Histopathology. 2022 Dec; 81(6):742-757.